CKD Bio Balance Sheet Health
Financial Health criteria checks 2/6
CKD Bio has a total shareholder equity of ₩131.6B and total debt of ₩157.3B, which brings its debt-to-equity ratio to 119.5%. Its total assets and total liabilities are ₩320.2B and ₩188.6B respectively.
Key information
119.5%
Debt to equity ratio
₩157.25b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩12.35b |
| Equity | ₩131.58b |
| Total liabilities | ₩188.59b |
| Total assets | ₩320.17b |
Recent financial health updates
Recent updates
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition
Feb 28
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?
Feb 01
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt
Jan 11What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us
Dec 21Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 30Financial Position Analysis
Short Term Liabilities: A063160's short term assets (₩136.1B) exceed its short term liabilities (₩87.3B).
Long Term Liabilities: A063160's short term assets (₩136.1B) exceed its long term liabilities (₩101.3B).
Debt to Equity History and Analysis
Debt Level: A063160's net debt to equity ratio (110.1%) is considered high.
Reducing Debt: Insufficient data to determine if A063160's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A063160 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A063160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.